Effects of estetrol/drospirenone versus ethinyl estradiol/drospirenone on glucose tolerance in women with polycystic ovary syndrome: A randomised controlled trial

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2025-09-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.70126PMID 40937537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lower reporting of venous thromboembolisms events with natural estrogen-based COCs compared to ethinylestradiol containing pills: A disproportionality analysis of the Eudravigilance database.

  2024cited by this paper
• Sample Sizes for Clinical Trials

  2024influential reference
• The effect of hormonal contraceptive therapy on clinical laboratory parameters: a literature review

  2023cited by this paper
• Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials.

  2022cited by this paper
• Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause

  2022cited by this paper
• Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone.

  2021cited by this paper
• Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome

  2018cited by this paper
• A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome.

  2017cited by this paper
• Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism

  2017cited by this paper
• U.S. Selected Practice Recommendations for Contraceptive Use, 2016.

  2016cited by this paper
• Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial

  2016cited by this paper
• Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome

  2016cited by this paper
• CLINICAL PRACTICE. Polycystic Ovary Syndrome.

  2016cited by this paper
• Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

  2015cited by this paper
• Birth Control in Clinical Trials

  2015cited by this paper
• The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage.

  2015cited by this paper
• The bencfit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers

  2014cited by this paper
• Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills.

  2013cited by this paper
• The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis

  2013cited by this paper
• Impact of combined oral contraceptives containing ethinylestradiol on the liver microsomal metabolism

  2013cited by this paper
• Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: A randomized study

  2013cited by this paper
• Ethinyl estradiol–drospirenone vs ethinyl estradiol–drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome

  2013cited by this paper
• Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

  2012cited by this paper
• Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive

  2011cited by this paper
• Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.

  2011cited by this paper
• Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.

  2011cited by this paper
• Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.

  2010cited by this paper
• Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review.

  2009cited by this paper
• Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome

  2008cited by this paper
• Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome

  2007cited by this paper
• Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation

  2006cited by this paper
• Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.

  2004cited by this paper
• A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.

  2003cited by this paper
• Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

  1999cited by this paper
• Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.

  1999cited by this paper
• A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome.

  1998cited by this paper
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  1998cited by this paper
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  1997cited by this paper
• Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

  1997cited by this paper
• Endocrine disorders

  1991cited by this paper
• Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin.

  1988cited by this paper

• No citing papers are available for this paper.